Roflumilast as a treatment for COPD
http://www.100md.com
《胸》
Specialist Registrar, Frenchay Hospital, Bristol, UK; ednash2000@hotmail.com
Rabe KF, Bateman ED, O’Donnell D, et al. Roflumilast—an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005;366:563–71
Chronic inflammation is the key pathophysiological mechanism in the development of COPD and there is increasing interest in the potential role of novel anti-inflammatory treatments. This phase III multicentre double blind study focuses on roflumilast, an oral phosphodiesterase 4 inhibitor.
1411 patients with stable moderate to severe COPD were randomised to receive placebo, roflumilast 250 μg once daily, or roflumilast 500 μg once daily for 24 weeks. The primary outcome measures were post-bronchodilator forced expiratory volume in 1 second (FEV1) and St George’s Respiratory Questionnaire (SGRQ) total score. Secondary outcome measures included the number of COPD exacerbations. The results showed a mean (SD) improvement in FEV1 of 74 (18) ml with roflumilast 250 μg and 97 (18) ml with roflumilast 500 μg compared with placebo at 24 weeks (p<0.0001). There were no significant differences in the SGRQ scores between the roflumilast and placebo groups. The mean number of exacerbations was reduced by 34% in the roflumilast 500 μg group compared with the placebo group, primarily due to a reduction in mild exacerbations (42%, p = 0.004). Adverse effects were predominantly gastrointestinal in nature and self-limiting.
This study provides encouraging initial data to support the use of roflumilast in patients with COPD. Further studies are needed to confirm that these results are sustained beyond 24 weeks and to assess further the effects on health-related quality of life.(E Nash)
婵烇絽娲犻崜婵囧閸涱喚顩烽柛娑卞墰鏉╂棃鏌涘▎蹇撯偓浠嬪焵椤掆偓閸犳稓妲愬┑鍥┾枖鐎广儱妫涢埀顒夊灦楠炲骞囬鍛簥婵炶揪绲惧ú鎴犵不閿濆拋鍤堝Δ锔筋儥閸炴挳鏌曢崱鏇犲妽閻㈩垰缍婇幊锟犲箛椤撶偟浠愰梺鍦瑰ú銈囨閳哄懎违闁稿本绋掗悗顔剧磼閺冨倸啸濠⒀勵殜瀵爼宕橀妸褎鍓戞繛瀛樼矊妤犲摜鏁锔藉婵＄偛澧界粙濠囨煛婢跺﹤鏆曟慨鐟邦樀閺佸秴鐣濋崘顭戜户闂佽鍠撻崝蹇涱敇缂佹ḿ鈻旈柣鎴烇供閸斿啴鏌￠崒姘煑缂佹顦遍埀顒冾潐缁繘锝為敃鍌氱哗閻犻缚娅ｇ粔鍨€掑顓犫槈闁靛洤娲ㄩ埀顒傤攰濞夋盯宕㈤妶鍥ㄥ鐟滅増甯楅～澶愭偣閸ワ妇涓茬紒杈ㄧ箘閹风娀鎮滈挊澶夌病婵炲濮鹃崺鏍垂閵娾晜鍋ㄥù锝呭暟濡牓姊洪锝嗙殤闁绘搫绻濋獮瀣箣濠婂嫮鎷ㄩ梺鎸庣☉閺堫剟宕瑰⿰鍕浄妞ゆ帊鐒﹂弳顏堟煕閹哄秴宓嗛柍褜鍓氬銊╂偂閿熺姴瑙﹂幖鎼灣缁€澶娒归崗鍏肩殤闁绘繃鐩畷锟犲礃閼碱剚顔戦梺璇″枔閸斿骸鈻撻幋鐐村婵犲﹤鍟幆鍌毭归悩鎻掝劉婵犫偓閹殿喚纾鹃柟瀵稿Х瑜版煡鏌涢幒鏂库枅婵炲懎閰ｆ俊鎾晸閿燂拷Rabe KF, Bateman ED, O’Donnell D, et al. Roflumilast—an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005;366:563–71
Chronic inflammation is the key pathophysiological mechanism in the development of COPD and there is increasing interest in the potential role of novel anti-inflammatory treatments. This phase III multicentre double blind study focuses on roflumilast, an oral phosphodiesterase 4 inhibitor.
1411 patients with stable moderate to severe COPD were randomised to receive placebo, roflumilast 250 μg once daily, or roflumilast 500 μg once daily for 24 weeks. The primary outcome measures were post-bronchodilator forced expiratory volume in 1 second (FEV1) and St George’s Respiratory Questionnaire (SGRQ) total score. Secondary outcome measures included the number of COPD exacerbations. The results showed a mean (SD) improvement in FEV1 of 74 (18) ml with roflumilast 250 μg and 97 (18) ml with roflumilast 500 μg compared with placebo at 24 weeks (p<0.0001). There were no significant differences in the SGRQ scores between the roflumilast and placebo groups. The mean number of exacerbations was reduced by 34% in the roflumilast 500 μg group compared with the placebo group, primarily due to a reduction in mild exacerbations (42%, p = 0.004). Adverse effects were predominantly gastrointestinal in nature and self-limiting.
This study provides encouraging initial data to support the use of roflumilast in patients with COPD. Further studies are needed to confirm that these results are sustained beyond 24 weeks and to assess further the effects on health-related quality of life.(E Nash)
|
閻庣敻鍋婇崰鏇熺┍婵犲洤妫橀柛銉㈡櫇瑜帮拷
闂佺ǹ绻楀▍鏇㈠极閻愮儤鍎岄柣鎰靛墮椤庯拷
闁荤姴娲ょ€氼垶顢欓幋锕€绀勯柣妯诲絻缂嶏拷
闂佺懓鍚嬬划搴ㄥ磼閵娾晛鍗抽柡澶嬪焾濡拷
闂佽浜介崝宀勬偤閵娧呯＜婵炲棙鍔栫粻娆撴煕濞嗘瑦瀚�
闂佸憡姊绘慨鎾矗閸℃稑缁╅柟顖滃椤ワ拷
|